



## **Texas Infertility Prevention Project (TIPP)**

## **Procedures of Collaboration**

To promote the identification, treatment, and prevention of sexually transmitted infections (STIs), the Department of State Health Services (DSHS) collaborates with a variety of state, local and regional partners including, but not limited to: local health departments; community-based clinics; sexual health, family planning, or other essential community providers; and state, local, and private laboratory partners (referred to as *partners* in this document).

DSHS and/or the Texas IPP administrative agency will utilize STI funds from the Centers for Disease Control and Prevention (CDC) and/or general revenue funds to conduct the following activities:

- a) Purchase and distribute chlamydia and gonorrhea (CT/GC) amplified technology test kits to project partners as agreed upon by all parties;
- b) Provide CT/GC laboratory processing (i.e., lab costs) for specimens from patients who have been tested (based on project screening criteria);\*
- c) Purchase and distribute medications to treat CT/GC through the DSHS Pharmacy Branch, PIOS;
- d) Provide statewide and partner site-specific CT/GC data analysis semi-annually and additional data analysis as requested on a case-by-case basis;
- e) Provide training, technical assistance, and programmatic consultation to project partners via telephone, written correspondence, and/or site visit;
- f) Provide staff and patient educational materials and online resources as appropriate; and
- g) Provide on-site administrative and clinical site audits to TIPP sites, including a clinical record review, to ensure policies, procedures, and practices are in compliance with program guidelines and objectives.

## Participating Project Partners will:

- a) Conduct CT/GC screening according to project screening guidelines\*/best practices, and ensuring patients will not be charged for test kits and/or laboratory processing supported by TIPP;
- b) Submit CT/GC specimens to an approved laboratory and accurately complete laboratory requisition forms to assure quality data and appropriate payor source\*\*;
- c) Submit data <sup>+</sup> required based on project data criteria and assure transmissions and correspondence meet security and confidentiality standards;
- d) Submit confidential reports of diagnosed STI cases to local health authority or DSHS surveillance as required by 25 Texas Administrative Code, Chapter 97;
- e) Provide patient care and document in accordance with the <u>DSHS HIV/STD Program Operation Procedures and Standards</u> (POPS) Chapter 12 STI Clinical Standards and the most current CDC STD Treatment Guidelines;
- f) Ensure medications obtained from DSHS through the Pharmacy Branch platform, PIOS, are used in accordance with the criteria set forth by DSHS;
- g) Maintain all records on all patients, participate in administrative and clinical site audits conducted by DSHS programmatic staff, Cardea staff and consultants, and/or project representatives, provide timely and thorough response to site audit feedback and reporting as requested;
- h) Comply with the Texas Administrative Code (TAC) Title 1, Part 15, Chapter 382, Subchapter A., <u>Healthy Texas</u> Women, 382.17 <u>HealthCare Providers</u> (b)-(d); and
- i) Assure all agency staff utilizing project supplies are oriented to project goals, mission, and screening guidelines.
- j) Maintain documentation of TIPP eligibility\* in client records.





**Note:** The Procedures of Collaboration may be renegotiated based on factors including, but not limited to: special project goals and objectives, partner agency capacity, screening volume, chlamydia and gonorrhea positivity rates, compliance with the most recent CDC STI Treatment Guidelines, adherence to the project screening guidelines, and available project funding.

Support to partners is non-monetary. Support includes CT/GC testing supplies, CT/GC laboratory processing, STI medications, training, technical assistance, and miscellaneous patient and staff education supplies.

\*Project CT/GC testing supplies are for a specified target population of uninsured individuals (<u>as defined in TIPP policy 420.002</u>) to assist public health/safety net providers maintain screening according to current screening guidelines and to meet community needs based on morbidity data.

\*\*Project partners are responsible for assuring allocated test supplies are used for specified project target population and the annual allocated supplies are expended routinely. Unused allocated supplies will be reallocated to other project partners as needed, and this could affect the next project year annual allocation. Project partners must ensure project tests are accurately reflected in laboratory invoices from participating private laboratories. If laboratory requisition forms are not completed accurately and project tests are not accounted for, the project may be unable to pay for missing tests due to the project funding cycle. If the project partner finds tests are not being accounted for on laboratory reports or invoices, notify the Coordinator immediately.

<sup>†</sup> Participating Project Partners must submit required data quarterly either through their CT/GC processing lab or clinic/agency data transfer through electronic health record system or other standardized reporting mechanism. Minimum required data elements: patient unique identifier, date of specimen collection, DOB, sex, race, ethnicity, test type, specimen source, CT test result, and GC test result.

## **Texas IPP Standards**

- Sexually Transmitted Infection Treatment Guidelines, (CDC), 2021.CDC STI Treatment Guidelines, 2021
  - Clinical Prevention Guidance
  - STD/HIV Prevention Counseling
  - Prevention Methods
  - Reporting and Confidentiality
  - Chlamydial Infections
  - Gonococcal Infections
- DSHS HIV/STD Program Operation Procedures and Standards (POPS); POPS Chapter 12 STI Clinical Standards
- <u>CDC Morbidity and Mortality Weekly Report (MMWR), Recommendations and Reports / January 3, 2020 / 68(5);1–20; Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020 / Commendations for Providing Quality Sexually Transmitted Diseases Clinical Services (Commendations Commendations Commenda</u>





tative Name P	Partner Representative Signature		Date Signed
Docusigned by:  Vanussa Sarria  FASFF18D4000402		11/14/2023	
Cardea Representative Signature		Date Signed	
- — DSHS Reg	presentative Signature	——————————————————————————————————————	igned
	Docusigne Vaussa FASFF18D2 Cardea Re	DocuSigned by:  Vanussa Sarria  FASFF18D4000402	Docusigned by:  Valuessa Sarria  FARFFIBD4000402  Cardea Representative Signature  Date